Improvement of the nonsense read-through therapy for muscular dystrophy by controlling nonsense mediated mRNA decay
Project/Area Number |
15K19641
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Pediatrics
|
Research Institution | Hyogo Medical University |
Principal Investigator |
LEE TOMOKO 兵庫医科大学, 医学部, 助教 (10596042)
|
Project Period (FY) |
2015-04-01 – 2018-03-31
|
Project Status |
Completed (Fiscal Year 2017)
|
Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Keywords | Duchenne型筋ジストロフィー / ナンセンス変異依存性mRNA分解 / リードスルー治療 / リードスルー / ナンセンス変異 |
Outline of Final Research Achievements |
The purpose of this study is to control nonsense-mediated mRNA decay(NMD)mechanism and improve the efficacy of read-thorough therapy for Duchenne muscular dystrophy (DMD). First, the system of identifying small mutations in DMD gene was constructed. Using this system, many DMD cases with nonsense mutation have been identified. Furthermore, the analysis system using fluorescent sequencer was developed for semi-quantitative analysis of mRNA from muscle. Based on these established systems, analysis to reveal and control NMD mechanism has been performed.
|
Report
(4 results)
Research Products
(1 results)